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Abstract
IgG is the predominant immunoglobulin in cervicovaginal mucus (CVM), yet how IgG in mucus 
can protect against infections is not fully understood. IgG diffuses rapidly through cervical mucus, 
slowed only slightly by transient adhesive interactions with mucins. We hypothesize this almost 
unhindered diffusion allows IgG to accumulate rapidly on pathogen surfaces, and the resulting 
IgG array forms multiple weak adhesive crosslinks to mucus gel that effectively trap (immobilize) 
pathogens, preventing them from initiating infections. Here, we report herpes simplex virus 
serotype 1 (HSV-1) readily penetrated fresh, pH-neutralized ex vivo samples of CVM with low or 
no detectable levels of anti-HSV-1 IgG, but was trapped in samples with even modest levels of 
anti-HSV-1 IgG. In samples with little or no endogenous anti-HSV-1 IgG, addition of exogenous 
anti-HSV-1 IgG, affinity purified from intravenous immunoglobulin, trapped virions at 
concentrations below those needed for neutralization and with similar potency as endogenous IgG. 
Deglycosylating purified anti-HSV-1 IgG, or removing its Fc component, markedly reduced 
trapping potency. Finally, a non-neutralizing IgG against HSV-gG significantly protected mice 
against vaginal infection, and removing vaginal mucus by gentle lavage abolished protection. 
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These observations suggest IgG-Fc has a glycan dependent “muco-trapping” effector function that 
may provide exceptionally potent protection at mucosal surfaces.
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INTRODUCTION
Large quantities of IgG are transported into female genital tract mucus secretions by the 
MHC class I-related neonatal Fc receptor,1 resulting in at least ten-fold more IgG than IgA.2 
However, despite this predominance of IgG, the precise mechanism(s) by which secreted 
IgG can prevent vaginal infections are not well understood. Few studies have explored the 
potential protective role of IgG within the mucus secretions overlaying the epithelial tissue, 
which sexually transmitted viruses invariably encounter and must penetrate in order to reach 
target cells. Well-known Ab effector functions in blood and lymph (e.g., complement 
activation, opsonization, and ADCC) are absent or limited in healthy female genital 
secretions, which typically have little complement activity and few if any active 
leukocytes.3-5 These classical mechanisms of systemic immune protection also do not 
adequately account for the moderate but significant protection observed in the landmark 
Thai RV144 HIV vaccine trial.6, 7 The vaccination regimen modestly reduced the risk of 
HIV acquisition despite inducing primarily non-neutralizing Ab and otherwise offering little 
to no protection against systemic progression of infections once acquired, suggesting that 
protection likely occurred prior to initiation of infection. A better understanding of potential 
additional mechanisms of vaginal mucosal immunity will also likely be critical for 
developing effective vaccines against other sexually transmitted infections, including HSV, 
which has been shown to evade complement and other classical antibody-mediated 
protective mechanisms.8-10
Here, we seek to explore the hypothesis that secreted IgG may have evolved to work in 
tandem with mucus to trap and thereby exclude individual pathogens.3 Viruses must 
penetrate cervicovaginal mucus (CVM) to reach and infect their target cells in the vaginal 
epithelium; indeed, we have shown that HIV and human papillomavirus (HPV) are both 
capable of rapidly diffusing through human genital mucus secretions.11, 12 We also 
previously found that the diffusion of IgG (11 nm) was slowed slightly in human cervical 
mucus compared to in saline buffer, while much larger virus-like particles, including the 
capsids of Norovirus (38 nm) and HPV (55 nm), were not slowed by this mucus.12 Thus, the 
slight retardation of the much smaller IgG molecules must be due to very transient (< 1 s), 
low-affinity bonds with the mucin mesh.12 These observations prompt our hypothesis that, 
by making only transient low-affinity bonds with mucins, IgG is able to diffuse rapidly 
through mucus and accumulate on a pathogen surface. The array of Ab bound to the 
pathogen surface can in turn effectively trap the pathogen in mucus gel by ensuring at least 
some low-affinity bonds to the mucin mesh are present at any given time. Virions trapped in 
CVM cannot reach their target cells, and will instead be shed with post-coital discharge 
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and/or inactivated by spontaneous thermal degradation or other protective factors in mucus, 
such as defensins.13, 14
RESULTS
Reduced HSV-1 mobility correlates with increasing endogenous anti-HSV-1 IgG in human 
CVM
We chose to explore this trapping-in-mucus hypothesis using HSV-1 (d ~180 nm), a highly 
prevalent sexually transmitted virus. We collected fresh, undiluted CVM obtained 
predominantly from donors with normal lactobacillus-dominated vaginal microbiota, as 
confirmed by Nugent scoring (Supplementary Table S1). HSV-1 virions expressing a VP22-
GFP tegument protein construct, packaged at high copy numbers while maintaining native 
viral envelope integrity, were mixed into CVM pH-neutralized to mimic neutralization by 
alkaline seminal fluid. We then performed time-lapse microscopy of virion motions in real-
time with high spatiotemporal resolution, and quantified virion mobility using multiple 
particle tracking over a long time scale. We observed substantial differences in HSV-1 
mobility in CVM samples from different donors (Figure 1a and Supplementary Videos S1 
and S2): in 7 of 12 CVM samples, most virions diffused distances spanning several microns 
over the course of 20 s, whereas in the remaining 5 CVM samples, the majority of virions 
were essentially trapped, moving less than their diameter (<200 nm) in 20 s.
Since IgG is the predominant immunoglobulin in human CVM,2 we examined whether 
virion mobility correlated with endogenous virus-specific IgG in all 12 CVM samples 
measured using a whole-virus ELISA assay (Supplementary Table S2). In good agreement 
with our hypothesis, HSV-1 diffused rapidly through all CVM samples that had little or no 
detectable endogenous anti-HSV-1 IgG (< 0.2 μg/mL; detection limit 0.017 μg/mL) at rates 
only several-fold lower than their expected rates in water (Figure 1, Supplementary Figure 
S1, and Supplementary Table S3). In contrast, in samples with elevated levels of 
endogenous anti-HSV-1 IgG (≥ 0.6 μg/mL), most HSV-1 virions were effectively trapped. 
HSV-1 that was trapped in place over the first 20 s observation remained trapped in the 
same locations for at least 15 min (Supplementary Video S3 and Supplementary Figure S2). 
In the same CVM samples, control latex nanoparticles comparable in size to HSV-1 and 
engineered with muco-inert coatings (PS-PEG; d ~200 nm) exhibited rapid diffusion (Figure 
1, Supplementary Video S4, and Supplementary Figure S1), in good agreement with our 
previous observations of the large pores present in human CVM (average ~340 nm).15, 16 
Thus, the mucus mesh spacing was large enough for IgG-coated HSV-1 (at most 15-20 nm 
larger diameter even at saturation) to diffuse relatively unimpeded in the absence of 
adhesive interactions with mucin gel. Muco-adhesive latex nanoparticles of the same size 
(PS; d ~200 nm) were markedly slowed or immobilized in the same CVM secretions (Figure 
1, Supplementary Video S5, and Supplementary Figure S1). Importantly, observations with 
PS-PEG and PS control particles confirmed that the general barrier properties of all samples, 
including those with low levels of endogenous anti-HSV-1 IgG, remained intact. After 
removal of ~90 95% of total IgG from these samples by dialysis at constant sample volume, 
HSV-1 became readily mobile (Supplementary Video S6 and Supplementary Figure S3), 
whereas PS beads remained immobilized (Supplementary Video S7 and Supplementary 
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Figure S3). HSV-1 mobility correlated only with endogenous HSV-1 specific IgG, and did 
not correlate with total IgG, IgA or IgM content (Supplementary Figure S4).
A well recognized mechanism of mucosal immune defense is ‘immune exclusion’ in which 
microorganisms in the gut are agglutinated by secreted polyvalent IgA and IgM into clusters 
too large to diffuse through mucus.17, 18 However, we observed little to no agglutinated 
HSV-1 in our experiments (see Supplementary Video S2 for example), consistent with 
previous findings that IgG is a relatively poor agglutinator.19 Together, these observations 
suggest that individual HSV-1 virions in samples with elevated endogenous levels of anti-
HSV-1 IgG are slowed or trapped by multiple low-affinity bonds with CVM rather than by 
physical (steric) obstruction.
HSV-1 is trapped by sub-neutralizing levels of exogenously added anti-HSV-1 IgG
To confirm that trapping of HSV-1 in CVM was mediated specifically by IgG bound to 
virions and not by any other component in mucus that might be associated with elevated 
endogenous anti-HSV-1 IgG, we affinity purified HSV-1 specific IgG from human 
intravenous immunoglobulin (starting with a pure clinical IgG preparation), and mixed the 
purified IgG into CVM samples that had low endogenous anti-HSV-1 IgG. We found that 
addition of 1 μg/mL anti-HSV-1 IgG trapped HSV-1 with a potency comparable to that of 
endogenous anti-HSV-1 IgG (Figure 2, Supplementary Video S8, and Supplementary Figure 
S5; p < 0.05 compared to native specimen without addition of anti-HSV-1 IgG). We further 
tested lower anti-HSV-1 IgG doses (Supplementary Videos S9-11), and observed potent 
trapping of virions when ~333 ng/mL anti-HSV-1 IgG was added (p < 0.05), and partial 
trapping at 100 and 33 ng/mL anti-HSV-1 IgG added (both p < 0.05). As controls, muco-
inert PS-PEG remained freely diffusive and muco-adhesive PS markedly slowed or 
immobilized in CVM samples treated with the highest anti-HSV-1 IgG doses 
(Supplementary Videos S12 and S13, respectively, and Supplementary Figure S6), 
confirming that the IgG did not cause HSV-1 trapping by altering mucus viscoelasticity or 
mesh spacing. Affinity-purified anti-HSV-1 IgG exhibited little neutralizing activity at 1 
μg/mL and ~333 ng/mL (Figure 2b), based on reduction of plaque formation in Vero cells, 
suggesting that multiple low-affinity bonds between IgG and CVM can trap virions at IgG 
levels lower than those needed to neutralize. HSV-1 was also trapped by a humanized 
monoclonal anti-gD IgG in CVM (Supplementary Video S14) but not by control, non-
specific IgG (Supplementary Video S15 and Supplementary Figure S7), underscoring the 
specificity of trapping via particular antibody-virus pairs, rather than a non-specific 
interaction or alteration of general mucus barrier properties. In good agreement with 
previous studies,12, 20 both polyclonal anti-HSV-1 IgG and monoclonal anti-gD IgG were 
only slightly slowed in CVM compared to saline (Supplementary Figure S8), suggesting 
both antibodies form only transient, low affinity bonds with CVM as individual molecules, 
yet facilitate effective trapping of virions once they accumulate on the viral surface by 
forming low-affinity but polyvalent IgG-mucin bonds.
IgG-mucus interaction is dependent on Fc-glycans
We next sought to determine the biochemical basis of the low-affinity bonds between IgG 
and CVM. The Fc domain of all IgGs harbors a conserved N-glycosylation site at Asn297, 
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and many IgG effector functions are Fc- and Asn297 glycan-dependent.21 Thus, we 
prepared F(ab')2 fragments (Figure 3a and Supplementary Figure S9) and deglycosylated 
IgG (Figure 3b) from the same affinity-purified anti-HSV-1 IgG to minimize any changes in 
HSV-1 binding avidity (confirmed by ELISA), and measured the mobility of HSV-1 pre 
mixed with these modified analogs prior to addition to CVM (premixed to minimize 
interference by endogenous HSV-1 specific IgG). We found both F(ab')2 and deglycosylated 
IgG exhibited substantially reduced trapping potency compared to intact IgG (Figure 3c; p < 
0.05), suggesting that the low affinity bonds IgG forms with mucins are not only Fc-
dependent, but also influenced by Fc glycosylation.
Non-neutralizing monoclonal IgG blocks vaginal HSV-2 infection in mice via IgG-mucus 
interactions
To determine whether trapping viruses in mucus can protect against infection in vivo, we 
evaluated the ability of a non-neutralizing monoclonal IgG1 to reduce HSV-2 transmission 
in the pH neutral22 mouse vagina. This monoclonal IgG1 binds to the relatively sparse gG 
surface glycoprotein, and exhibited no neutralization activity across all concentrations tested 
in vitro (Figure 4a); mouse IgG1 also possesses little to no complement23-25 and ADCC26, 27 
activity. We challenged mice vaginally with 2 ID50 HSV-2 with and without anti-gG IgG1, 
and assayed HSV infection by detection of virus shedding in vaginal lavages three days post 
inoculation, a more sensitive assay of infection than visual observation of lesions, viral 
isolation from sacral ganglia, or death.28 Anti-gG IgG1, at a concentration of 3.3 μg/mL and 
above, significantly protected against infection and reduced the average viral load compared 
to either medium alone or control, non specific IgG (Figure 4a and Supplementary Figure 
S10, p < 0.05). Interestingly, anti-gG IgG1 appeared to only reduce the rate of successful 
vaginal HSV transmission; in mice that became infected, the extent of vaginal infection was 
comparable to that in mice receiving control IgG, suggesting that the anti-gG IgG dosed did 
not elicit effector functions that reduced the extent of virus spread in infected mice 
compared to control IgG (Supplementary Figure S10). We also evaluated protection in mice 
that received a gentle vaginal wash to remove mucus without detectable trauma to the 
epithelium (Figure 4b and Supplementary Figure S11). The removal of CVM increased 
susceptibility to HSV-2 in control mice from ~70% to ~100% but not the degree of HSV 
shedding in mice that became infected (Supplementary Figure S10). This moderate (~30%) 
increase in susceptibility is likely attributed to loss of innate protection by CVM itself: a 
CVM layer prevents immediate direct contact between viruses and the epithelium, and 
contains factors, such as defensins, that may further contribute to overall reduction 
infectious HSV flux to the epithelium. More importantly, removal of CVM completely 
abolished the ~50% extra protection (from ~70% to ~20% infection) afforded by anti-gG 
IgG1 in native mice that cannot be attributed to innate immunity (Figure 4c). Consistent with 
the hypothesis that trapping in mucus may facilitate protection, these results together suggest 
much of the observed synergistic enhancement in protection by anti-gG IgG1 when CVM is 
present most likely occurred prior to HSV reaching target cells, rather than by immune 
mechanisms that can facilitate protection at the cellular level (e.g., complement or ADCC). 
Our observations are also consistent with the poor complement and ADCC activity of mouse 
IgG1, as well as numerous previous studies that have shown HSV can evade complement 
and other classical immune protective mechanisms.810, 29, 30 Since even a non-neutralizing 
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monoclonal IgG against a relatively sparse surface antigen can afford substantial protection, 
monoclonals against more abundant surface antigens, such as gD and gB, or those optimized 
to maximize interactions with mucus are likely to provide even more potent protection at 
mucosal surfaces in vivo.
DISCUSSION
The first evidence of antibody-mucin affinity can be traced back more than 30 years, when 
Kremer and Jager noted that infertility in humans is often caused by anti-sperm 
antibodies.31, 32 In cervical mucus samples with high levels of anti-sperm Ab, they found 
that both individual and agglutinated sperm make no forward progress and shake in place for 
hours until they die, despite vigorous flagellar motility. More recently, Phalipon et al. 
suggested secretory IgA can aggregate pathogenic Shigella flexneri in mouse nasal mucus 
secretions via the secretory component, anchoring the bacteria to the mucus gel and thereby 
‘excluding’ them from infectious entry.33 In both of the above instances, the authors 
assumed that the antibodies were attached firmly to the mucins. However, FRAP 
experiments by Olmsted et al.,12 and those here, clearly demonstrate that IgG and other Ab 
diffuse rapidly in human genital mucus, slowed only slightly and transiently compared to 
their diffusion in water, and with no non-recoverable fraction indicative of permanently 
immobilized Ab. Using a complementary technique called fluorescence imaging of profiles 
(FIP), Saltzman et al. also showed similar rapid Ab diffusion in human cervical mucus.20 
Such rapid diffusion of individual Ab molecules in mucus can only be explained by weak 
and short-lived adhesive interactions between Ab and the mucin mesh. Thus, trapping of 
individual sperm or pathogens by specific Ab in mucus gel most likely reflects multiple 
weak interactions between mucins and an array of bound Ab. These results contrast sharply 
with recent work by Fahrbach et al. that suggested endogenous IgG binds tightly to 
mucins.34 This discrepancy is likely due to experimental artifacts from the use of 
fluorescently-tagged Ab to label endogenous Ab in the latter work, which would create large 
immune complexes that exhibit far slower diffusivity than individual Ab molecules, 
consequently misinterpreted as high affinity binding of individual Ab molecules to mucins.
The mucin-like Fcγ binding protein (FcγBP) has also been proposed to serve an 
immunological role in mucus through its ability to bind strongly to IgG-Fc.35 Nevertheless, 
more recent evidence indicates the primary function of FcγBP is instead to stabilize 
gastrointestinal mucus gel by covalently cross-linking Muc2 mucins.36, 37 An IgG Fc-FcγBP 
mucin crosslinking mechanism that relies on strong binding of IgG by FcγBP also directly 
contradicts numerous prior efforts that have failed to detect any significant binding of 
individual Ab to mucins.3, 12, 20, 38, 39 Finally, FcγBP binds broadly to all IgG, and the 
interaction is thus subject to competitive inhibition.40 In our experiments where exogeneous 
HSV-1 specific IgG was added to CVM, total levels of IgG already present in the samples 
were hundreds- to thousands-fold higher than the HSV-1 specific IgG doses added. Thus, for 
FcγBP to be responsible for the observed trapping phenomena, FcγBP must have been 
present in greater molar quantities than native IgG, which is unlikely given that the protein 
has not been routinely identified in proteomic screens of human genital tract fluid (see 
Andersch-Bjorkman et al.41 vs. others42-44). In contrast to previous studies, by examining 
the effect of IgG on virions in mucus gel rather than probing directly for interactions 
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between individual IgG molecules and mucins, we were able to document not only the 
potent trapping of individual virions by multiple surface-bound IgG (Figure 5), but also that 
the IgG-mucin interactions are Fc- and glycan-dependent.
We have previously shown that HIV-1 and HSV-1 can be effectively immobilized in acidic, 
lactic acid-rich CVM (at least 1000 fold reduced Deff compared to in buffer).11, 16 However, 
both virions readily penetrate more pH-neutral mucus, similar to mucus secretions exposed 
to alkaline semen or depleted of lactobacilli, such as in women with bacterial vaginosis.45 
The ability for IgG-mucin interactions to trap virions (~1500 fold reduced Deff compared to 
in buffer) may therefore provide a crucial mechanism to effectively reinforce the mucus 
barrier. The extent of reduction in virus mobility observed here contrasts sharply with 
observations by Shukair et al.,46 who reported an activity in genital mucus specimens from 
HIV negative women (i.e., free of virus-specific IgG) that hindered HIV mobility by only a 
few-fold on average. The mucus layer coating the female reproductive tract may be only 
~50-100 μm thick, and readily penetrated by virions within minutes even if they are slowed 
a few fold in mucus compared to in buffer.11 Thus, to effectively reduce the flux of virions 
reaching target cells, it is likely essential for virions to be slowed by orders of magnitude.
Trapping virions in genital tract mucus should markedly reduce heterosexual transmission of 
viral infections. Women acquire many of the major sexually transmitted viral infections 
(e.g., HIV, HPV, and HSV) at rates on the order of 1 per 100 to 1000 sex acts on average 
(see Supplementary Text). This suggests few if any of these virions are able to infect target 
cells per intercourse, which reflects a combination of the diffusional and other innate barrier 
properties of genital secretions. Therefore any reduction in the flux of virions that reach 
target cells should proportionally reduce transmission rates. Indeed, the effectiveness of the 
IgG-mucin interactions reported here may be reflected in part by the clinical observation that 
HSV vaginitis is generally less common than HSV infection of the anogenital skin (vulva 
and groin), which are not protected by genital mucus secretions. Blocking initial infection 
altogether, rather than attempting to clear initial infections, may be especially critical for 
infections that are difficult, if not impossible, to cure once established (e.g., HSV, HIV). Our 
findings not only underscore the importance of monitoring both mucosal and systemic 
immune responses, but also motivate developing vaccines that elicit sufficient secreted Ab 
to trap pathogens in mucus in addition to eliciting neutralizing titers of systemic Ab. In the 
recent gD2-AS04 HSV vaccine trial,47, 48 protective efficacy was initially observed in 
seronegative women but not in men or seropositive women, and a larger study of 
seronegative women revealed only moderate efficacy against HSV-1 (~35% efficacy against 
HSV-1 infection and 58% efficacy against HSV-1 genital disease) but interestingly no 
protection against HSV-2. In both studies, the vaccine elicited neutralizing serum Ab against 
HSV as well as HSV specific cellular immune responses in all women and men. However, 
because mucosal levels of Ab were not monitored, it remains unclear whether what little 
protection was observed could have correlated with mucosal Ab response. It is likely that 
generating sufficient mucosal Ab levels remains a major bottleneck to an effective HSV 
vaccine. Inducing secreted Ab that bind to ‘non-neutralizing’ surface epitopes should trap 
pathogens as effectively as those that bind to neutralizing epitopes, a prospect that may 
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broaden potential antigen targets for vaccine development, especially against virions with 
rapidly evolving neutralizing epitopes.
Fc-mediated trapping of pathogens in mucus, which directly blocks infections at the portals 
of entry, may represent an exceptionally potent mechanism by which the immune system 
can rapidly adapt and reinforce multiple mucosal surfaces against diverse and rapidly 
evolving pathogens. In pilot studies, we found LPS-specific monoclonal IgG, but not control 
IgG, immobilized individual Salmonella typhimurium in mucus secretions lining mouse 
gastrointestinal tract tissues without inhibiting the flagella beating apparatus and without 
causing aggregation, i.e., independent of the classical, aggregation based mechanism of 
immune exclusion (data not shown; Subramani, Lai). The observed trapping in both CVM 
(predominantly Muc5b mucins) and gastrointestinal mucus (Muc2 mucins) suggests the 
molecular basis for Fc-mucin affinity may be common among major secreted mucins – the 
long densely glycosylated fibers that form mucus gels – and possibly mediated by glycans, 
since sugars represent the major constituent of mucins (up to 80% by dry weight49). 
Nevertheless, significant technical challenges remain in elucidating the precise entities on 
mucins responsible for the observed Fc mucin affinity because biochemical perturbations of 
the mucus gel typically destroy the native mucin mesh microstructure and gel 
viscoelasticity50 needed to trap pathogens in the gel. Improved understanding of the 
molecular basis of Fc-mucin affinity will likely offer critical insight into understanding and 
identifying subpopulations with greater susceptibility to infection, as well as therapeutic 
strategies to enhance this mucosal immune protective mechanism.
MATERIALS AND METHODS
Culture and purification of fluorescent HSV-1
The HSV-1 mutant 166v,51 encoding a VP22-Green Fluorescent Protein (GFP) tegument 
protein packaged into HSV-1 at relatively high copy numbers,52 was kindly provided by 
Richard Courtney and used in all microscopy and ELISA studies, besides those for in vivo 
experiments. The addition of GFP to the VP22 protein appears to have no deleterious effects 
on viral replication,51 and the fluorescence of 166v was consistently more intense than that 
of HSV-1 mutants encoding other GFP fusion proteins. 166v was expanded at an MOI of 3 
on confluent monolayers of HaCat cells maintained in DMEM (Life Technologies, Grand 
Island, NY) supplemented with 5% FBS, 1× L-glutamine and 1× Penicillin/Streptomycin. 
Culture medium was collected 16-18 hr post infection and twice centrifuged at 1000 ×g for 5 
min to remove cell debris. The resulting supernatant was split into 30 mL aliquots and 
precipitated overnight with a polyethylene glycol (PEG)/salt solution. Briefly, 10 mL of 1.55 
M NaCl was added to 30 mL of crude virus supernatant, followed by 10 mL of 40% PEG 
8000 (Sigma, St. Louis, MO). After an overnight incubation at 4°C the virus/PEG solution 
was centrifuged at 2555 ×g and 4°C for 1 hr. The virus pellet was then resuspended in 1× 
PBS and centrifuged through a continuous 20-50% (w/w) sucrose in PBS gradient for 1 hr at 
74,119 ×g. The resulting virus band was collected, diluted 1:5 in PBS, layered over 30% 
(w/w) sucrose in PBS, and centrifuged for 1.5 hr at 83,472 ×g to pellet virus for further 
purification. Purified virus pellet was resuspended in PBS and stored as single use aliquots 
at –80°C.
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Cervicovaginal mucus (CVM) collection and characterization
CVM collection was performed as published previously.11, 16 Briefly, undiluted CVM 
secretions, averaging 0.3 g per sample, were obtained from women of reproductive age, 
ranging from 20 to 32 years old (27.4 ± 0.9 years, mean ± SEM), by using a self sampling 
menstrual collection device following protocols approved by the Institutional Review Board 
of the University of North Carolina – Chapel Hill. Informed consent of participants was 
obtained after the nature and possible consequences of the study were explained. 
Participants inserted the device into the vagina for at least 30 s, removed it, and placed it 
into a 50 mL centrifuge tube. Samples were centrifuged at 230 ×g for 2 min to collect the 
secretions. Aliquots of CVM for lactic acid and Ab measurements (diluted 1:5 with 1× PBS 
and stored at –80°C) and slides for gram staining were prepared immediately, and the 
remainder of the sample was stored at 4°C until microscopy, typically within a few hours. 
Samples were collected at random times throughout the menstrual cycle, and cycle phase 
was estimated based on the last menstrual period date normalized to a 28 day cycle. No 
samples were ovulatory based on visual observation (none exhibited spinnbarkeit). Samples 
that were non uniform in color or consistency were discarded. Donors stated they had not 
used vaginal products nor participated in unprotected intercourse within 3 days prior to 
donating. All samples had pH <4.5; none had bacterial vaginosis (BV) based on Gram 
staining and Nugent scoring, following scoring criteria described previously.53 For lactic 
acid and Ab measurements, CVM aliquots were thawed and centrifuged for 2 min at 21,130 
×g to obtain cell free supernatant containing lactic acid and Ab. Lactic acid content was 
measured using a D-/L-lactic acid kit (R Biopharm, Darmstadt, Germany) according to 
manufacturer protocol, but adapted to a 96-well format. Methods for Ab measurements are 
detailed in the Supplementary Materials and Methods.
Preparation and characterization of anti-HSV-1 Ab
Anti-HSV-1 IgG was affinity purified from intravenous immunoglobulin, and used to 
prepare anti-HSV-1 F(ab')2 and deglycosylated anti-HSV-1 IgG. Detailed methods are 
provided in the Supplementary Materials and Methods.
Neutralization assay
Purified HSV-1 (~550 PFU; 5 μL) was incubated with 95 μL of HSV-1 specific IgG solution 
at different final concentrations for 1 hr with end over end mixing. The mixture was then 
diluted with 210 μL of media, of which duplicate 150 μL aliquots were transferred to 
confluent Vero cell monolayers in a 6 well plate. Plates were incubated at 37 °C for 1 hr 
with periodic rocking to ensure that the plates did not dry out, before the HSV-1/Ab mixture 
was aspirated off and wells were washed with 2 mL of PBS. The plates were then incubated 
for 3 days at 37°C in 2% carboxymethyl cellulose in EMEM supplemented with 1× L-
glutamine and 1× Penicillin/Streptomycin, before staining with 1% crystal violet solution, 
and the resulting plaques were manually counted and compared to control wells to determine 
the extent of neutralization.
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Fluorescence recovery after photobleaching (FRAP)
FRAP was performed following methods similar to those described by Olmsted et al. FITC-
labeled Ab was added to mucus or saline at 10% v/v and gently stirred to achieve uniform 
distribution. FRAP experiments were conducted using an LSM 510 confocal microscope, 
with a roughly 40 μm × 40 μm ROI bleached with 405/488 lasers at 100% laser intensity 
over ~3 sec. For mucus samples, ROIs were chosen to minimize epithelial cells within the 
bleached volume. After bleaching, the fluorescence intensity of Ab was monitored over time 
with background subtracted out and values adjusted for photobleaching of the entire image 
over time based on control ROIs.
Multiple particle tracking of HSV-1 in CVM
To mimic neutralization of CVM by alkaline seminal fluid, we titrated CVM to pH 6.8-7.1 
using small volumes (~3% v/v) of 3 N NaOH, and confirmed pH using a micro pH electrode 
(Microelectrodes, Inc., Bedford, NH) calibrated to pH 4, 7 and 10 buffers. Samples were 
either untreated or treated by addition of known amounts of purified anti-HSV-1 IgG or 
control (anti-biotin) IgG. Control beads consisted of red or green fluorescent 200 nm 
carboxyl-modified polystyrene particles (Molecular Probes, Eugene, OR), either uncoated 
(PS; muco-adhesive) or covalently conjugated with low molecular weight (2 kDa), amine-
functionalized polyethylene glycol (PEG; Rapp Polymere, Tuebingen, Germany) to produce 
coated particles (PS-PEG; muco-inert), as previously described.15 Fluorescent virions or 
control beads (approximately 108–109 particles/mL) were added at 5% v/v to 20 μL of CVM 
placed in a custom made glass chamber, and incubated for 1 hr at 37°C prior to microscopy. 
The translational motions of the particles were recorded using an EMCCD camera (Evolve 
512; Photometrics, Tucson, AZ) mounted on an inverted epifluorescence microscope 
(AxioObserver D1; Zeiss, Thornwood, NY), equipped with an Alpha Plan Apo 100x/1.46 
NA objective, environmental (temperature and CO2) control chamber and an LED light 
source (Lumencor Light Engine DAPI/GFP/543/623/690). Videos (512 × 512, 16-bit image 
depth) were captured with MetaMorph imaging software (Molecular Devices, Sunnyvale, 
CA) at a temporal resolution of 66.7 ms and spatial resolution of 10 nm (nominal pixel 
resolution 0.156 μm/pixel) for 20 s. The tracking resolution was determined by tracking the 
displacements of particles immobilized with a strong adhesive, following a previously 
described method.54 Particle trajectories were analyzed using MetaMorph software as 
described previously;11, 15, 16 image contrast was adjusted to improve particle visibility, but 
the same contrast level was applied throughout the entire video and did not bias toward any 
particle population. Sub-pixel tracking resolution is obtained by determining the precise 
location of the particle centroid by light-intensity-weighted averaging of neighboring pixels. 
Trapped particles were defined as those with effective diffusivity (Deff) < 0.01 μm2/s at a 
time scale (τ) of 1 s (i.e., particles move less than their diameter within 1 s). In a subset of 
experiments, we confirmed that particles defined as trapped over the course of 20 s based on 
this criterion remain confined to the same locations over more than 15 min. The slope α of 
the log-log mean square displacement (<MSD>) vs. time scale plot provides a further 
measure of particle mobility: α = 1 for pure unobstructed Brownian diffusion, e.g., particles 
in water, α becomes smaller as obstruction to particle diffusion increases, and α is zero for 
permanently trapped particles. At least five independent experiments in CVM from different 
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donors, with n ≥100 particles per experiment, were performed for each condition. For a 
subset of donors, similar observations were made at least twice in samples obtained on 
separate days to ensure reproducibility, but only one sample was used for analysis.
Mouse vaginal HSV-2 challenge model
All experiments conducted with mice were performed in accordance with protocols 
approved by the Johns Hopkins University Animal Care and Use Committee satisfying the 
requirements of the E.E.C. Guidelines (1986) and U.S. Federal Guidelines (1985). Female 
CF-1 mice (6-8 weeks old; Harlan, Frederick, MD) were treated with Depo-Provera® 
(medroxyprogesterone acetate, 2.5 mg/mouse) by subcutaneous injection into the right flank 
6-8 days prior to use. Depo-Provera® synchronizes mice in a prolonged diestrus like state, 
in which the vaginal epithelium thins and susceptibility of the tissue to infection increases.55 
Depo Provera®-treated mice were randomly divided into groups of ten. The mouse vagina is 
pH neutral;22 therefore, we did not attempt to modify vaginal pH prior to inoculation. 
Inocula were prepared by mixing HSV-2 (final dose 2 ID50; strain G, ATCC, Manassas, 
VA) with medium or different concentrations of control (anti-biotin) or anti-gG IgG (8.F.
141; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and incubating for 1 hr at 37°C. 
Mice were inoculated with 20 μL of HSV-2 solution, delivered to the vagina using a 50 KL 
Wiretrol (Drummond, Broomall, PA), fire-polished to avoid damage to the vaginal 
epithelium. In some studies, the mouse vagina was gently washed with ~10 mL of normal 
saline delivered at 1 mL/min through a smooth ball-tipped gavage needle connected to a 
syringe pump, prior to HSV-2 challenge. Removal of mucus by this process was measured 
using a fluorimetric mucin assay, as previously described.56 Importantly, the gentle wash 
did not damage the vaginal epithelium, as confirmed by microscopy with a fluorescence-
based dead cell stain (YOYO-1) that assesses membrane integrity,55 compared to 
conventional lavage and/or vaginal swabbing with a cotton tip, which induced significant 
epithelial damage. YOYO-1 has been previously used to reveal toxicity caused by detergent-
based microbicides that led to increased susceptibility to HSV infection.55 Tissue sectioning 
and H&E staining was performed by the Animal Histopathology lab at the University of 
North Carolina – Chapel Hill. Infection was assayed three days post-inoculation by detection 
of virus in vaginal lavages. Briefly, 50 μL of medium was pipetted in and out of the vagina 
20 times, diluted to 0.2 mL and placed on target cells (ELVIS® HSV Test System; 
Diagnostic Hybrids, Athens, OH); infected cells (foci) were identified one day later, 
following manufacturer protocol. Scores for virus shedding were assigned on a scale of 0-4 
based on the approximate density of foci observed (“0”: 0; “0.5”: <100; “1”: 100 500; “2”: 
500 1000; “3”: 1000+; “4”: saturated). At least three independent experiments were 
performed for each condition, with n = 10 animals per experimental group (n ≥ 30 total).
Statistical analysis
Correlation between endogenous anti-HSV-1 IgG levels and average particle or virus Deff in 
individual CVM samples was measured using Pearson’s correlation coefficient (r). 
Statistical comparisons were limited to two groups (test group compared with the 
appropriate control group performed during the same experiment). Fisher’s exact test was 
used to determine the statistical significance of reductions in % mice infected. A two tailed 
Student’s t test (paired for comparisons of Ab-treated vs. native CVM for the same CVM 
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samples) was used for all other comparisons. Differences were deemed significant at an 
alpha level of 0.05. All values are reported as mean ± SEM unless otherwise indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HSV-1 is immobilized in cervicovaginal mucus (CVM) samples with elevated endogenous 
anti-HSV-1 IgG but readily mobile in samples with low endogenous anti-HSV-1 IgG. 
Fluorescent HSV-1 or control particles were added to CVM, and their motions were 
analyzed by multiple particle tracking methods. (a) Representative 20 s traces of HSV-1 (d 
~180 nm) and control particles (d ~200 nm) with effective diffusivity (Deff) at a time scale τ 
of 1 s within one SEM of the mean. Control particles include muco inert (PEG coated; PS 
PEG) and muco adhesive (uncoated; PS) polystyrene beads, which are freely diffusive and 
trapped in human CVM, respectively, as previously shown.15 (b) Geometric average Deff (τ 
= 1 s) for PS-PEG, PS and HSV-1 in individual CVM samples from unique donors (n = 12, 
each experiment performed independently) as a function of endogenous anti-HSV-1 IgG. 
Dashed lines represent the Deff cutoff below which particles are permanently trapped 
(moving less than their diameter within 1 s). Pearson's correlation coefficients (r) are 
indicated.
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Anti-HSV-1 polyclonal human IgG added to cervicovaginal mucus (CVM) samples with 
low endogenous anti-HSV-1 IgG potently traps HSV-1. HSV-1 mobility was quantified in 
aliquots of the same CVM samples with different amounts of anti-HSV-1 IgG added. (a) 
Comparison of effective diffusivity (Deff; τ = 1 s) for HSV-1 in CVM samples (n = 7, each 
experiment performed independently) with different amounts of total anti-HSV-1 IgG (sum 
of endogenous and added IgG). Different colored circles represent distinct samples. (b) In 
vitro neutralization vs. trapping potency of anti-HSV-1 IgG. Neutralization was assayed 
based on reduction of HSV plaque formation in Vero cells; trapping was defined as Deff (τ = 
1 s) below 0.01 μm2/s. See Materials and Methods for additional details. Total IgG was 
averaged across samples for each treatment group. Error bars represent SEM. * indicates 
statistically significant difference compared to respective controls (p < 0.05). (c) 
Distribution of particle speeds in samples treated with 1 μg/mL IgG (annulus chart), and 
estimated concentration of total IgG (μg/mL) needed for 50% trapping (number in center). 
Donor ID is indicated for each sampl,e with colors matching those in (a).
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IgG mucin affinity is Fc and glycosylation dependent. (a) Preparation of anti-HSV-1 F(ab')2 
confirmed by SDS PAGE; full length gel is presented in Supplementary Figure S9. (b) 
Preparation of deglycosylated anti-HSV-1 IgG confirmed by lectin-binding assay 
(absorbance of IgG bound ConA normalized to amount of IgG). Error bars represent SEM. 
(c) Mobility (Deff; τ = 1 s) of HSV-1 in cervicovaginal mucus (CVM) with low endogenous 
anti-HSV-1 IgG incubated with various HSV-1 specific Ab: 1 Kg/mL affinity purified 
native IgG (“Intact”), 667 ng/mL F(ab')2, and 1 g/mL deglycosylated IgG compared to 
HSV-1 in native CVM (“None”). Distinct samples (n = 4 5, each experiment performed 
independently) are indicated with different color circles; averages are indicated by solid 
lines. Dashed line represents the Deff cutoff below which particles are permanently trapped 
(moving less than their diameter within 1 s). * indicates statistically significant difference (p 
< 0.05).
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A non-neutralizing monoclonal IgG against the gG epitope protects against vaginal HSV-2 
infection in mice via IgG-mucus interactions. (a) In vivo protection vs. in vitro 
neutralization (% Neut.) of HSV-2. Neutralization was assayed based on reduction of HSV 
plaque formation in Vero cells. Depo-Provera®-treated mice were inoculated with HSV-2 
mixed with control or anti-gG IgG. Infection was assayed three days post inoculation by 
detection of virus in vaginal lavages using the ELVIS® HSV Test System. (b) Mucin 
concentration in vaginal fluid collected from the native or gently washed mouse vagina, and 
YOYO-1 staining for vaginal epithelial cell damage in gently washed or conventionally 
lavaged and swabbed (cotton tip) mice. N.D. = no data. (c) In vivo protection by 33 μg/mL 
anti-gG IgG is lost when mouse CVM is removed by gentle washing using a syringe pump. 
Data represent at least three independent experiments, each with n = 10 mice per group (in 
vivo; total n = 40 per group for data in (a), n ≥ 30 for (c)) or performed in triplicate (in 
vitro). Error bars represent SEM. * indicates statistically significant difference compared to 
control (p < 0.05).
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Proposed mechanism of Ab-mediated trapping of viruses in mucus. Schematic showing (a) 
HSV readily penetrates native CVM with little to no endogenous anti-HSV IgG, and (b) 
anti-HSV IgG traps HSV in CVM by multiple transient, low affinity bonds with mucins. By 
forming only short-lived, low affinity bonds with mucus, free Ab, such as IgG, are able to 
diffuse rapidly through mucus and bind to viruses. As IgG molecules accumulate on the 
virus surface, they form multiple low-affinity bonds between the virus and mucus gel. A 
sufficient number of these transient low-affinity bonds ensure viruses are effectively trapped 
in mucus at any given time, thereby reducing the flux of infectious virions that can reach 
target cells. In a similar fashion, IgM, with its 10 relatively low-affinity Fab components, is 
well known to make essentially permanent polyvalent ‘high avidity’ bonds. Arrows indicate 
the small fraction of free (not virus-bound) IgG (~10-20%) that will interact with mucins at 
any moment in time 3, 12.
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